Acrivon Therapeutics (ACRV) News Today $8.01 +0.01 (+0.13%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 8.3% in OctoberOctober 31 at 1:46 AM | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest UpdateAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 1,110,000 shares, a decline of 8.3% from the September 30th total of 1,210,000 shares. Based on an average daily trading volume, of 90,900 shares, the short-interest ratio is currently 12.2 days. Approximately 5.1% of the company's shares are sold short.October 30 at 1:38 AM | marketbeat.comAcrivon Therapeutics: Promising Innovations in WEE1/PKMYT1 Inhibition and AP3 Platform Drive Buy RatingOctober 29, 2024 | markets.businessinsider.comAcrivon Therapeutics: Buy Rating Driven by Promising Oncology Advancements and Strategic PositioningOctober 29, 2024 | markets.businessinsider.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 5.5% in SeptemberAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,210,000 shares, a drop of 5.5% from the September 15th total of 1,280,000 shares. Based on an average trading volume of 93,600 shares, the days-to-cover ratio is presently 12.9 days. Currently, 5.6% of the company's stock are sold short.October 17, 2024 | marketbeat.comAcrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 16, 2024 | globenewswire.comAcrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology PipelineOctober 12, 2024 | finance.yahoo.comAcrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent ActivityOctober 11, 2024 | globenewswire.comAcrivon Therapeutics (NASDAQ:ACRV) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comMarshall Wace LLP Raises Stock Holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)Marshall Wace LLP lifted its holdings in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 58.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 948,866 shares of the company's stock afOctober 2, 2024 | marketbeat.comPerceptive Advisors LLC Has $31.09 Million Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)Perceptive Advisors LLC lifted its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 78.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,360,858 shares of the company's stocSeptember 30, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 24.3% in SeptemberAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totalling 1,280,000 shares, a growth of 24.3% from the August 31st total of 1,030,000 shares. Currently, 5.9% of the company's shares are short sold. Based on an average daily volume of 101,600 shares, the days-to-cover ratio is currently 12.6 days.September 28, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Position Raised by Sands Capital Ventures LLCSands Capital Ventures LLC grew its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 28.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,122,605 shares of tSeptember 21, 2024 | marketbeat.comAcrivon shares maintain buy rating on positive analyst ratingSeptember 18, 2024 | uk.investing.comAcrivon Therapeutics maintains Buy rating from H.C. Wainwright with steady price targetSeptember 18, 2024 | uk.investing.comBreaking Down Acrivon: Deep Dive Into Revenue, Profitability, And ProspectsSeptember 18, 2024 | seekingalpha.comAcrivon Therapeutics: Buy Rating Justified by Promising Clinical Data and Strategic Research InitiativesSeptember 18, 2024 | markets.businessinsider.comLadenburg Thalmann Upgrades Acrivon Therapeutics (ACRV)September 17, 2024 | msn.comTD Cowen Remains a Buy on Acrivon Therapeutics, Inc. (ACRV)September 17, 2024 | markets.businessinsider.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Recommendation of "Buy" from AnalystsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been assigned an average recommendation of "Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 12 month price objective among brokeSeptember 17, 2024 | marketbeat.comJMP Securities Reaffirms Market Outperform Rating for Acrivon Therapeutics (NASDAQ:ACRV)JMP Securities reiterated a "market outperform" rating and set a $17.00 price target on shares of Acrivon Therapeutics in a research report on Monday.September 16, 2024 | marketbeat.comAcrivon Therapeutics' (ACRV) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $22.00 target price on shares of Acrivon Therapeutics in a report on Monday.September 16, 2024 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Raised to "Buy" at LADENBURG THALM/SH SHLADENBURG THALM/SH SH raised Acrivon Therapeutics from a "neutral" rating to a "buy" rating and set a $16.00 target price on the stock in a report on Monday.September 16, 2024 | marketbeat.comAcrivon Therapeutics, Inc.: Strong Buy on Robust Clinical Data and Strategic Market PositioningSeptember 16, 2024 | markets.businessinsider.comAcrivon Therapeutics, Inc.: Strong Buy on Positive ACR-368 Therapy Data and Market PositioningSeptember 15, 2024 | markets.businessinsider.comAcrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data AnalysisSeptember 14, 2024 | globenewswire.comAcrivon Therapeutics to Present at the Cantor Global Healthcare ConferenceSeptember 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acrivon Therapeutics Amid Promising Cancer Program Prospects and Strong Market PotentialSeptember 9, 2024 | markets.businessinsider.comAcrivon Therapeutics (NASDAQ:ACRV) Receives Buy Rating from Piper Sandler CompaniesPiper Sandler Companies restated a "buy" rating and issued a $30.00 target price on shares of Acrivon Therapeutics in a research note on Friday.September 6, 2024 | marketbeat.comWe're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash WiselySeptember 5, 2024 | finance.yahoo.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of "Moderate Buy" by AnalystsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has received an average recommendation of "Moderate Buy" from the six research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the comAugust 23, 2024 | marketbeat.comAcrivon Therapeutics: A Buy Rating Justified by Clinical Advances and Financial StabilityAugust 16, 2024 | markets.businessinsider.comBMO maintains Outperform rating on Acrivon Therapeutics sharesAugust 16, 2024 | uk.investing.comAcrivon Therapeutics (NASDAQ:ACRV) Posts Earnings ResultsAcrivon Therapeutics (NASDAQ:ACRV - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $0.08.August 14, 2024 | marketbeat.comAcrivon Therapeutics, Inc.: Strong Buy Rating on Robust Financials and Promising Clinical DataAugust 13, 2024 | markets.businessinsider.comPromising Acrivon Trial Results and Market Opportunity Support Buy RatingAugust 13, 2024 | markets.businessinsider.comAcrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 13, 2024 | finance.yahoo.comBuy Rating Affirmed on Acrivon Therapeutics Amid Anticipated Clinical Updates and Novel Treatment ApproachesAugust 13, 2024 | markets.businessinsider.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Rating of "Moderate Buy" by BrokeragesAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to thJuly 4, 2024 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Trading 1% Higher Acrivon Therapeutics (NASDAQ:ACRV) Stock Price Up 1%July 2, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six haveJune 9, 2024 | marketbeat.comAcrivon Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 29, 2024 | globenewswire.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) to Post Q2 2024 Earnings of ($0.48) Per Share, HC Wainwright ForecastsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Investment analysts at HC Wainwright boosted their Q2 2024 earnings estimates for Acrivon Therapeutics in a report issued on Tuesday, May 14th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.48) per sMay 17, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Acrivon Therapeutics, Inc. (ACRV)May 14, 2024 | markets.businessinsider.comACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024May 14, 2024 | investorplace.comAcrivon Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 14, 2024 | globenewswire.comAcrivon Therapeutics Inc ACRVMay 11, 2024 | morningstar.comWhile institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownershipMay 9, 2024 | finance.yahoo.comLadenburg Thalmann Downgrades Acrivon Therapeutics (ACRV)April 30, 2024 | msn.comLADENBURG THALM/SH SH Lowers Acrivon Therapeutics (NASDAQ:ACRV) to NeutralLADENBURG THALM/SH SH downgraded Acrivon Therapeutics from a "buy" rating to a "neutral" rating in a research note on Monday.April 29, 2024 | marketbeat.com Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here ACRV Media Mentions By Week ACRV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRV News Sentiment▼0.960.43▲Average Medical News Sentiment ACRV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRV Articles This Week▼42▲ACRV Articles Average Week Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcutis Biotherapeutics News Today Applied Therapeutics News Today Prothena News Today Cullinan Therapeutics News Today Zymeworks News Today Phibro Animal Health News Today Rapport Therapeutics News Today Pliant Therapeutics News Today Tyra Biosciences News Today AnaptysBio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRV) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
